UK biotech led investment in the European market in the first quarter of 2026, new figures from the BioIndustry Association (BIA) show. 

The BIA report shows renewed financing was driven by a rebound in venture capital investment and a broader distribution of funding across companies and stages. 

Total equity financing reached £552 million ($746 million) between January and March 2026, up from £466 million ($629 million) in Q4 2025, marking a stronger start to the year for the UK’s biotech sector.  

Venture capital was the primary driver, rising 17% quarter‑on‑quarter to £516 million ($697 million) from £442 million ($597 million), signalling growing investor confidence following a prolonged period of caution. 

 While headline totals remain below the £924 million ($1.2 billion) recorded in Q1 2025, last year’s figures were skewed by a small number of mega‑rounds. By contrast, Q1 2026 was characterised by a broader spread of investment, with capital deployed across more companies and stages.  

The UK also secured 57% of all European biotech venture capital this quarter, the highest European tally – an indicator of the ongoing strength of the UK market. 

“It comes as great relief to see those green shoots that started showing end of 2025 grow into a more sustained and healthier shift in market dynamics in the first quarter of 2026,” said Jane Wall, Managing Director of BIA.  

“While headline figures often fluctuate based on the presence of a few megadeals, the underlying story of Q1 is one of accelerating momentum and a broader distribution of capital across the UK’s innovative ecosystem. 

 “As we move further into 2026, the architecture for growth is building with strong political support. With deal flow broadening and international interest in our world-class ecosystem high, now is the time to ensure that domestic capital follows the lead of our global peers to fully unlock the value of UK innovation and that the government delivers its broader commitments through the Life Sciences Sector Plan.”